The promise
to effectively
treat cancer

The promise
to effectively

Company Highlights

Novel Technology

Novel MIRP™ technology to generate a
family of immuno-recruitment drugs for
multiple cancers

Promising Programs

Ongoing Phase I/II for solid tumors
Collaboration with ROCHE
to combine with Atezolizumab

Active pipeline

DSP107 - Phase I/II
DSP105 - IND Q4 2021
TSP - Multiple future candidates in R&D

Growing Market

Immuno-therapeutics market
to grow to
$56.5B by 2025

Solid IP Portfolio

12 families
2 granted patents in US and ROW
10 pending patents worldwide

Strong Leadership

Seasoned management team
and KOL support: technology inventor,
Prof. Mark Tykocinski

Contact Us

KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196